Natera, Inc. ($NTRA) Stock Forecast: Down 5.3% Today

What is Natera, Inc.?

Natera Inc. (NASDAQ: NTRA) is a biotech company specializing in genetic testing services, with a focus on prenatal testing, oncology, and personalized medicine. The company has been making strides in the biotech sector with its innovative technologies and services.

Why is Natera, Inc. going down?

NTRA stock is down 5.3% on May 15, 2026 14:36

• Natera's stock experienced a strong bearish movement of 5.9% today.
• The market reacted negatively to Natera's Q1 2026 earnings report despite raising its 2026 revenue and gross margin guidance. This can be attributed to the wider net loss of US$85.09 million due to increased operating expenses for clinical trials, new products, and international expansion.
• Cathie Wood's ARK Invest's strategic shift towards increasing its stake in Natera while selling shares in other biotech companies may have also influenced market sentiment, signaling a shift in focus within the biotech sector.
• Analysts' mixed reactions to Natera's first-quarter results, with revenue beating expectations but statutory losses being larger than forecast, could have added to the overall bearish sentiment surrounding the stock.

NTRA Price Chart

NTRA Technical Analysis

NTRA News

(NTRA) Movement as an Input in Quant Signal Sets

This article analyzes Natera Inc. (NASDAQ: NTRA) using AI-generated quantitative signals, highlighting a weak near-term sentiment but strong long-term outlook. It presents three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—alongside a multi-timeframe signal analysis indicating varying support and resistance levels. The analysis identifies an exceptional 59.6:1 risk-reward setup targeting a 17.1% gain.

https://news.stocktradersdaily.com/news_release/150/NTRA_Movement_as_an_Input_in_Quant_Signal_Sets_051426080601_1778803561.html

Cathie Wood’s ARK sells Twist Bioscience, buys Natera stock

Cathie Wood's ARK Invest has continued to rebalance its biotech portfolio, selling shares in Twist Bioscience, CareDx, and Adaptive Biotechnologies. Concurrently, ARK significantly increased its stake in Natera, acquiring over 17,000 shares across its ARKK and ARKG ETFs. These actions demonstrate a strategic shift within the biotech sector, focusing on growth opportunities in Natera while reducing exposure to other holdings.

https://www.investing.com/news/company-news/cathie-woods-ark-sells-twist-bioscience-buys-natera-stock-93CH-4686944

Natera, Inc. (NASDAQ:NTRA) Just Released Its First-Quarter Earnings: Here's What Analysts Think

This article provides an analysis of Natera, Inc.'s first-quarter earnings, highlighting key financial outcomes such as revenue and earnings per share. It also presents the updated outlook and price targets from analysts following the earnings release. The report aims to give investors an understanding of Natera's recent performance and future expectations as perceived by financial experts.

https://www.moomoo.com/news/post/69920437/natera-inc-nasdaq-ntra-just-released-its-first-quarter-earnings

Analysts Have Made A Financial Statement On Natera, Inc.'s (NASDAQ:NTRA) First-Quarter Report

Natera, Inc. recently reported mixed first-quarter results, with revenues beating expectations but statutory losses being larger than forecast. Analysts have since updated their 2026 forecasts, upgrading revenue and loss per share estimates, though the price target remains largely unchanged. Despite anticipated slower revenue growth compared to its industry peers, the overall sentiment shows a moderate uplift.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/analysts-have-made-a-financial-statement-on-natera-incs-nasd

Why Natera (NTRA) Is Down 5.9% After Raising 2026 Guidance But Posting a Wider Q1 Loss

Natera (NTRA) saw its stock drop by 5.9% despite raising its 2026 revenue and gross margin guidance after its Q1 2026 earnings report. While the company achieved record testing volumes and revenue growth to US$696.64 million, its net loss widened to US$85.09 million due to increased operating expenses for clinical trials, new products, and international expansion. This outcome highlights the ongoing tension for Natera between strong growth and the challenge of achieving profitability amidst significant investment.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/why-natera-ntra-is-down-59-after-raising-2026-guidance-but-p

Trending Today

WEX Inc. ($WEX) Stock Forecast: Up 5.4% Today

Salesforce.com Inc ($CRM) Stock Forecast: Up 5.2% Today

Albemarle Corporation ($ALB) Stock Forecast: Down 5.2% Today

Adobe Inc. ($ADBE) Stock Forecast: Up 5.1% Today

Jetblue Airways Corporation ($JBLU) Stock Forecast: Down 5.0% Today

Workday Inc. ($WDAY) Stock Forecast: Up 5.1% Today

Clear Secure Inc. ($YOU) Stock Forecast: Up 5.5% Today

DocuSign Inc. ($DOCU) Stock Forecast: Up 5.0% Today

DexCom Inc. ($DXCM) Stock Forecast: Up 6.0% Today

Coty Inc. Class A ($COTY) Stock Forecast: Down 6.8% Today

Natera, Inc. Price History

08.04.2026 - NTRA Stock was down 7.7%

• Despite strong revenue growth driven by successful products like Fetal Focus and Signatera MRD test, Natera faced a bearish movement in its stock, potentially linked to a wider net loss reported in the same quarter, raising concerns about profitability.
• The missed EPS estimate and increased operating expenses leading to a higher net loss are likely factors contributing to the negative market sentiment towards Natera.
• Investors may be concentrating on the company's ability to manage expenses and bottom line performance, somewhat overshadowing the positive revenue growth and raised revenue guidance for the full year.
• The market's response could also be influenced by the stock's recent underperformance compared to the broader market, despite surpassing revenue expectations, suggesting a possible mismatch in investor expectations and market valuation.

15.04.2026 - NTRA Stock was down 5.3%

• Natera's stock experienced a strong bearish movement of 5.9% today.
• The market reacted negatively to Natera's Q1 2026 earnings report despite raising its 2026 revenue and gross margin guidance. This can be attributed to the wider net loss of US$85.09 million due to increased operating expenses for clinical trials, new products, and international expansion.
• Cathie Wood's ARK Invest's strategic shift towards increasing its stake in Natera while selling shares in other biotech companies may have also influenced market sentiment, signaling a shift in focus within the biotech sector.
• Analysts' mixed reactions to Natera's first-quarter results, with revenue beating expectations but statutory losses being larger than forecast, could have added to the overall bearish sentiment surrounding the stock.

14.03.2026 - NTRA Stock was up 5.1%

• William Blair started covering Natera with an Outperform rating, emphasizing the company's market position and growth prospects, likely boosting investor confidence.
• A favorable interim futility analysis from Allogene Therapeutics' trial utilizing Natera's CLARITY™ MRD assay showed promising results in large B-cell lymphoma, contributing to the positive sentiment surrounding Natera.
• A court ruling ordering a 30% ongoing royalty for Natera in a patent dispute is a significant win, reinforcing the company's intellectual property rights and potentially increasing future revenue.
• Despite a decrease in price, the increase in trading volume after the legal victory indicates investor interest and optimism in Natera's future financial performance, as they anticipate the impact of these events on upcoming earnings.

14.03.2026 - NTRA Stock was up 5.8%

• Today's positive performance by Natera is linked to William Blair's initiation of coverage on the company, endorsing its strong position in diagnostic markets and growth potential.
• The encouraging interim futility analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial, which uses Natera's CLARITY™ MRD assay, also contributed to the optimistic outlook by demonstrating successful MRD clearance in high-risk patients.
• Furthermore, a recent court ruling that mandates a 30% ongoing royalty payment to Natera in a patent dispute is seen as a significant victory for the company, reinforcing its intellectual property rights and hinting at future financial gains.
• Despite concerns such as potential overvaluation and insider sales, Natera's leadership in the market, early-mover advantage, and progress in cancer research are likely bolstering investor confidence in its future growth opportunities.

17.03.2026 - NTRA Stock was up 5.1%

• Natera (NTRA) reported impressive fourth-quarter results, exceeding earnings and revenue estimates, which likely boosted investor confidence in the company's performance.
• Positive interim futility analysis from Allogene Therapeutics' ALPHA3 trial, utilizing Natera's CLARITY™ MRD assay, showcased the effectiveness of Natera's technology in identifying high-risk patients and potentially preventing relapse in large B-cell lymphoma cases.
• Despite holding a Zacks Rank #4 (Sell) due to estimate revisions, the initiation of coverage by William Blair with an "outperform" recommendation highlighted Natera's strong position in the growing MRD testing market, projecting significant revenue growth potential.
• The mixed share price performance evaluation, indicating undervaluation by DCF model but overvaluation by P/S ratio, suggests varying perspectives on Natera's future valuation and growth prospects, leaving investors with contrasting views on the stock's true value.

23.03.2026 - NTRA Stock was down 5.2%

• The recent bearish movement in Natera's stock could be attributed to:
• Profit-taking by insiders: Co-founder Sheena Jonathan and family trusts selling a significant number of shares could have indicated a lack of confidence in the short-term performance of the stock.
• Overvaluation concerns: Despite the recent price surge, valuation metrics like the Price-to-Sales (P/S) ratio suggesting overvaluation might have led investors to capitalize on their gains.
• Market dynamics: While Natera's stock experienced a downward trend, other companies in the healthcare sector, such as UFP Technologies, Mettler-Toledo, and Viatris, saw substantial gains, potentially diverting investor attention away from Natera.
• Overall market sentiment: The reopening of the Strait of Hormuz resulting in decreased logistics and energy costs may have redirected investor focus to companies directly benefiting from these changes, impacting Natera's stock negatively.

16.03.2026 - NTRA Stock was down 6.8%

• The bearish movement in Natera's stock today could be attributed to the mixed evaluations of its share price performance, with conflicting assessments of undervaluation and overvaluation.
• Despite being positioned to capture a significant share of the $20 billion MRD opportunity and receiving an 'Outperform' rating from William Blair, concerns about overvaluation and insider selling may have dampened investor sentiment.
• The positive interim results from Allogene Therapeutics’ ALPHA3 trial, showcasing the effectiveness of cema-cel in reducing MRD levels in lymphoma patients, could have been overshadowed by broader market uncertainties or profit-taking activities.
• Natera's strong growth potential and competitive advantages in the diagnostics sector may still underpin its long-term prospects, despite short-term market fluctuations.

06.04.2026 - NTRA Stock was up 5.1%

• The bullish movement in Natera's stock today is linked to positive developments such as an "Outperform" rating from William Blair, a patent victory, and promising study results for its Signatera assay.
• The selling of shares by key executives like Sheena Jonathan, John Fesko, and CEO Steven Chapman to cover tax obligations initially raised concerns. However, these pre-arranged transactions, in light of positive news, likely reassured investors about the company's health and future prospects.
• Strategic selling of shares by company insiders under Rule 10b5-1 plans, despite the stock being down year-to-date, may indicate a prudent approach to finance management while maintaining confidence in company performance.
• The combination of positive company developments and strategic insider selling likely fueled the bullish movement in Natera's stock today, demonstrating a blend of financial responsibility and investor confidence in the company's growth trajectory.

30.03.2026 - NTRA Stock was up 5.1%

• The company revealed its first-quarter financial results and held a conference call, potentially boosting investor confidence and fueling the bullish movement.
• Insider selling by the co-founder and CEO, aimed at covering tax obligations, initially raised concerns but a clarified context of these sales being part of a pre-arranged trading plan may have alleviated any negative impact.
• Despite Natera's current lack of profitability, positive court rulings and new analyst coverage could have positively influenced investor sentiment, contributing to the bullish market performance.
• Taken together, positive updates on financial results, structured insider trading activities, and external factors like court decisions and analyst coverage likely played a role in Natera's recent strong bullish trend.

29.03.2026 - NTRA Stock was down 5.0%

• The downward trend in Natera's stock price could be linked to notable insider selling activity by directors such as Roelof Botha, Eric H. Rubin, and Ruth Williams Brinkley. This activity may have sparked concerns among investors regarding the company's future outlook.
• Despite the release of positive information regarding Natera's recent clinical evidence for its Prospera transplant test, which could potentially boost revenue, the overall market sentiment may have been clouded by the insider selling, as well as the company's negative net margins and ROE.
• While the initial increase in M&T Bank Corp's stake could have been viewed as a positive development, investor focus appeared to shift towards the insider selling and the company's financial difficulties, contributing to today's bearish movement in the stock.

08.04.2026 - NTRA Stock was down 6.0%

• Natera's strong revenue growth and milestone of processing over 1 million tests in a quarter showcased its continued expansion and market demand for its services.
• The wider loss per share than expected could have contributed to the bearish movement in the stock, despite positive revenue performance.
• The sale of shares by the Executive Chairman to cover tax obligations may have also impacted investor sentiment, leading to a decline in the stock price.
• Overall, while Natera's operational performance remains robust, market reaction to the earnings miss and insider selling likely drove the bearish movement in the stock today.

11.04.2026 - NTRA Stock was up 5.1%

• Despite concerns over its high valuation influencing a decline in stock price, Natera's impressive Q1 earnings call, demonstrating revenue growth and increased volume, has boosted investor confidence.
• Analysts have raised the 12-month price target to $260.78, indicating a 19% potential upside, reflecting optimism regarding Natera's future performance.
• The unexpected Q4 profit of US$47.3 million has shifted focus from prior losses to potential growth, although discussions on the stock's valuation persist among investors.
• Analysts' continued Buy rating and optimistic outlook, with target prices spanning from $136 to $285, further bolster the positive trajectory of Natera's stock.